Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514398 | 0.85 | HRH3 (0.60) | HRH3NFE2L2ITGB3ITGA2BLTA4H | |
| SCHEMBL19309189 | 0.85 | PARP10 (0.54) | HRH3LTA4HEPHX2HPGD | |
| SCHEMBL10744094 | 0.84 | HRH3 (0.58) | HRH3NFE2L2ITGB3ITGA2BLTA4H | |
| SCHEMBL3513377 | 0.81 | HRH3 (0.53) | HRH3NFE2L2ITGB3ITGA2BHPGD | |
| SCHEMBL3507790 | 0.81 | HRH3 (0.53) | HRH3NFE2L2ITGB3ITGA2BHPGD | |
| SCHEMBL5206609 | 0.81 | HRH3 (0.53) | HRH3NFE2L2ITGB3ITGA2BHPGD | |
| SCHEMBL4522084 | 0.81 | HRH3 (0.48) | HRH3ACHELTA4HEPHX2HPGD | |
| SCHEMBL30102042 | 0.81 | PARP10 (0.52) | HRH3LTA4HEPHX2HPGD | |
| SCHEMBL27981217 | 0.80 | HRH3 (0.60) | HRH3NFE2L2LTA4HHPGDPTGES | |
| SCHEMBL23642802 | 0.79 | PARP15 (0.51) | LTA4HEPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1740540-A1 | PHENYL ACETAMIDES | Bayer HealthCare AG (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2005103001-A1 | PHENYL ACETAMIDES | BAYER HEALTHCARE AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1572628-A1 | ISOPHTALIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052839-A1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | LTC4S, LTB4R2, LTB4R | HRH3 1299/4885NFE2L2 238/4885ACHE 1163/4885 |
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | HRH3 1425/4885NFE2L2 107/4885ACHE 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.